Corvus Pharmaceuticals, Inc.
corporate_fare Company Profile
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for CRVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for CRVS spans 8-K, 10-Q, 424B5, 10-K.
Recent high-impact activity:
- Corvus Q3 2026: $202.9M Cash Funds Operations Into Q2 2028 as Soquelitinib Trials Advance
- Corvus Launches Phase 1B Trial of Soquelitinib in Hidradenitis Suppurativa
- Corvus Invests $5M in Angel Pharma to Advance Soquelitinib Trials in China
- Corvus Pharma's Soquelitinib Shows Durable Remissions, Favorable Safety in Phase 1 Trial
- Corvus Pharma Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Highlighting Durable Remissions
Financial Snapshot
Short Interest & Short Volume
18.85 days to coverFINRA reported short interest of 17,759,451 shares in CRVS as of the October 30, 2026 settlement, a 1.2% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 45.7% of CRVS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.